SIRNA AGAINST CBL-B AND OPTIONALLY IL2 UND IL12 FOR USE IN THE TREATMENT OF CANCER

• Main Authors: LOIBNER, HANS, HASLINGER, ISABELLA, SEIDL, SANDRA, SCHUSTER, MANFRED, LAMETSCHWANDTNER, GUENTHER
• Format: Patent
• Language: English; French; German
• Published: 05.07.2012
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Die vorliegende Erfindung betrifft ein Verfahren zur Immunaktivierung von NK-Zellen durch Reduzierung oder Inhibierung der Cb1-b Funktion in den NK-Zellen. Dadurch wird das angeborene Immunsystem stimuliert wodurch die Therapie geeigneter Krankheiten ermöglicht wird. The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases. L'invention concerne un procédé d'activation immunitaire des cellules NK par réduction ou inhibition de la fonction Cb1-b dans ces dernières. Ce procédé a pour effet de stimuler le système immunitaire inné ce qui permet le traitement de pathologies appropriées.